keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/28209912/detection-efficacy-of-hybrid-68-ga-psma-ligand-pet-ct-in-prostate-cancer-patients-with-biochemical-recurrence-after-primary-radiation-therapy-defined-by-phoenix-criteria
#1
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, Markus Krönke, Christoph Rischpler, Gregor Habl, Sabrina Dewes, Armin Ott, Hans-Jürgen Wester, Markus Schwaiger, Tobias Maurer, Matthias Eiber
The aim of this retrospective study was to evaluate the detection rate of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA ligand) positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrent prostate cancer (PC) defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment. Methods: 118 patients were finally eligible for this retrospective analysis with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range: 2.2-158...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28197764/new-frontiers-in-prostate-cancer-imaging-clinical-utility-of-prostate-specific-membrane-antigen-positron-emission-tomography
#2
REVIEW
Asim Afaq, Deepak Batura, Jamshed Bomanji
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway. Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment. Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition...
February 14, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28195907/solitary-psma-positive-pulmonary-metastasis-in-biochemical-relapse-of-prostate-cancer
#3
Nils Groe Hokamp, Carsten Kobe, Eric Linzenich, David Maintz, Alexander Drzezga
A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1.60 ng/mL). Ga PSMA PET/CT identified a solitary, PSMA-positive pulmonary nodule in the right lung. After resection, histologic analysis confirmed prostatic origin, and the blood PSA level decreased to 0.13 ng/mL. Solitary pulmonary metastasis from prostate cancer is rare. The benefits of local treatment of a single metastasis even in advanced disease are disputed among oncologists...
February 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28193503/clinical-translation-of-a-psma-inhibitor-for-99m-tc-based-spect
#4
Guillermina Ferro-Flores, Myrna Luna-Gutiérrez, Blanca Ocampo-García, Clara Santos-Cuevas, Erika Azorín-Vega, Nallely Jiménez-Mancilla, Emmanuel Orocio-Rodríguez, Jenny Davanzo, Francisco O García-Pérez
BACKGROUND: Prostate-specific membrane antigen (PSMA) is highly over-expressed in advanced prostate cancers. (68)Ga-labeled PSMA inhibitors (iPSMA) are currently used for prostate cancer detection by PET imaging. The availability of simple, efficient and reproducible radiolabeling procedures is essential for developing new SPECT radiopharmaceuticals for clinical translation. The aim of this research was to prepare (99m)Tc-EDDA/HYNIC-Lys(Nal)-Urea-Glu ((99m)Tc-EDDA/HYNIC-iPSMA) obtained from lyophilized kit formulations and evaluate the in vitro and in vivo radiopharmaceutical binding to prostate cancer cells over-expressing PSMA, as well as the (99m)Tc-EDDA/HYNIC-iPSMA normal biodistribution in humans and the preliminary uptake in patients with prostate cancer...
February 3, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28191563/dendritic-poly-chelator-frameworks-for-multimeric-bioconjugation
#5
Dominik Reich, Alexander Wurzer, Martina Wirtz, Veronika Stiegler, Philipp Spatz, Julia Pollmann, Hans-Jürgen Wester, Johannes Notni
Starting from multifunctional triazacyclononane-triphosphinate chelator cores, dendritic molecules with the ability to bind metal ions within their framework were synthesized. A cooperative interaction of the chelator cages resulted in a markedly increased affinity towards (67/68)Ga(III). A hexameric PSMA inhibitor conjugate with high affinity (IC50 = 1.2 nM) and favorable in vivo PET imaging properties demonstrated practical applicability. The novel scaffolds are useful for synthesis of structurally well-defined multimodal imaging probes or theranostics...
February 13, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28168589/impact-of-pet-acquisition-durations-on-image-quality-and-lesion-detectability-in-whole-body-68-ga-psma-pet-mri
#6
Benjamin Noto, Florian Büther, Katharina Auf der Springe, Nemanja Avramovic, Walter Heindel, Michael Schäfers, Thomas Allkemper, Lars Stegger
BACKGROUND: While (68)Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and quantification was investigated. To this end, whole-body PET list mode data from 12 patients with prostate cancer were acquired 1 h after injection of 2 MBq/kg [(68)Ga]HBED-CC-PSMA on a hybrid PET-MRI system...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28166149/incidental-detection-of-head-and-neck-squamous-cell-carcinoma-on-68ga-psma-11-pet-ct
#7
Courtney Lawhn-Heath, Robert R Flavell, Christine Glastonbury, Thomas A Hope, Spencer C Behr
We present a case of an incidentally detected squamous cell carcinoma of the oropharynx on Ga-PSMA-11 PET. A 71-year-old man's condition was diagnosed as prostate carcinoma after a year of rising serum prostate-specific antigen. The staging Ga-PSMA PET/CT demonstrated focal radiotracer uptake in the prostate corresponding to his known primary prostate cancer. However, a PSMA-avid 3.4-cm mass was incidentally found in the right tongue base that was biopsied, confirming squamous cell carcinoma.
February 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28138747/-68-ga-psma-11-pet-ct-in-primary-staging-of-prostate-cancer-psa-and-gleason-score-predict-the-intensity-of-tracer-accumulation-in-the-primary-tumour
#8
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Elisabeth von Guggenberg, Dorota Kendler, Lorenza Scarpa, Gianpaolo di Santo, Llanos Geraldo Roig, Johanna Maffey-Steffan, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: Prostate cancer (PC) cells typically show increased expression of prostate-specific membrane antigen (PSMA), which can be visualized by (68)Ga-PSMA-11 PET/CT. The aim of this study was to assess the intensity of (68)Ga-PSMA-11 uptake in the primary tumour and metastases in patients with biopsy-proven PC prior to therapy, and to determine whether a correlation exists between the primary tumour-related (68)Ga-PSMA-11 accumulation and the Gleason score (GS) or prostate-specific antigen (PSA) level...
January 31, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28134694/pulmonary-opacities-and-bronchiectasis-avid-on-68ga-psma-pet
#9
Kirsten Bouchelouche, Mikkel Holm Vendelbo
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and the expression increases with tumor aggressiveness, metastatic disease, and recurrence. Despite its name, PSMA is also expressed in neovasculature of other tumors including lung cancer. Here, we demonstrate a case of increased PSMA expression on Ga-PSMA PET/CT in benign lung opacities and bronchiectasis in a prostate cancer patient. Thus, increased PSMA activity in the lungs may be due to both benign and malignant diseases and warrants further evaluation...
January 27, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28131751/18f-psma-1007-pet-ct-detects-micrometastases-in-a-patient-with-biochemically-recurrent-prostate-cancer
#10
Frederik L Giesel, Claudia Kesch, Mijin Yun, Jens Cardinale, Uwe Haberkorn, Klaus Kopka, Clemens Kratochwil, Boris A Hadaschik
No abstract text is available yet for this article.
December 29, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28131698/incidental-detection-of-tracer-avidity-in-meningioma-in-68-ga-psma-pet-ct-during-initial-staging-for-prostate-cancer
#11
T K Jain, A G S Jois, S Kumar V, S K Singh, R Kumar, B R Mittal
No abstract text is available yet for this article.
January 25, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28126683/pet-imaging-of-64-cu-dota-scfv-anti-psma-lipid-nanoparticles-lnps-enhanced-tumor-targeting-over-anti-psma-scfv-or-untargeted-lnps
#12
Patty Wong, Lin Li, Junie Chea, Melissa K Delgado, Desiree Crow, Erasmus Poku, Barbara Szpikowska, Nicole Bowles, Divya Channappa, David Colcher, Jeffrey Y C Wong, John E Shively, Paul J Yazaki
INTRODUCTION: Single chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due to their fast urinary clearance. METHODS: An anti-prostate membrane antigen (PSMA) scFv with a site-specific cysteine was expressed and evaluated in a prostate cancer xenograft model by Cu-64 PET imaging. To enhance tumor accumulation, the scFv-cys was conjugated to the co-polymer DSPE-PEG-maleimide that spontaneously assembled into a homogeneous multivalent lipid nanoparticle (LNP)...
January 17, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28116853/utility-of-68-ga-prostate-specific-membrane-antigen-positron-emission-tomography-in-diagnosis-and-response-assessment-of-recurrent-renal-cell-carcinoma
#13
Shankar Siva, Jason Callahan, David Pryor, Jarad Martin, Nathan Lawrentschuk, Michael S Hofman
INTRODUCTION: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) is an emerging imaging modality in prostate cancer. However, (68) Ga-PSMA-PET may also have diagnostic utility in the setting of renal cell carcinoma (RCC). We investigate the differential role of (18) F-fluorodeoxyglucose (FDG) and PSMA-PET/CT scanning in patients with oligometastatic RCC. In particular, we focus on the utility of PSMA-PET for diagnostic evaluation of isolated or limited metastases planned for local surgery or radiation, as well as the potential utility of PSMA-PET for therapeutic response assessment in patients receiving stereotactic ablative body radiotherapy (SABR)...
January 24, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28114227/psma-uptake-in-mediastinal-sarcoidosis
#14
Philip Junior Ardies, Pieterjan Gykiere, Lode Goethals, Johan De Mey, Frank De Geeter, Hendrik Everaert
Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein which is frequently overexpressed on prostate cancer cells. Ga-PSMA PET/CT plays an increasing role in prostate cancer management. However, growing evidence suggests increased PSMA uptake in a variety of other malignant tumor entities and in some benign lesions. This report describes PSMA uptake in numerous thoracic lymph nodes in a patient with known mediastinal sarcoidosis. Knowledge and recognition of these possibilities are important to avoid scan misinterpretation...
January 20, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28114225/subcutaneous-lobular-capillary-hemangioma-on-68ga-psma-pet-ct
#15
Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Søren Høyer, Kirsten Bouchelouche
We present a case of a subcutaneous process in the abdominal wall with high prostate-specific membrane antigen (PSMA) activity on Ga-PSMA PET/CT. Histology demonstrated a benign lobular capillary hemangioma with a high vascular density, with highly PSMA-positive endothelial cells. It is well known that PSMA is expressed in different tissue, including neovasculature in various malignant tumors, and the knowledge is rapidly evolving as new discoveries appear.
January 20, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28110348/erratum-to-a-rare-case-of-rectal-carcinoma-and-prostate-carcinoma-with-coexistent-paget-s-disease-mimicking-bone-metastases-in-both-18f-fdg-and-68ga-psma-pet-ct
#16
Arun Sasikumar, Ajith Joy, M R A Pillai, Vikraman Raman, Arun Vasudevan, Jayaprakash Madhavan
No abstract text is available yet for this article.
January 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28103574/68ga-psma-11-pet-ct-for-prostate-cancer-staging-and-risk-stratification-in-chinese-patients
#17
Shiming Zang, Guoqiang Shao, Can Cui, Tian-Nv Li, Yue Huang, Xiaochen Yao, Qiu Fan, Zejun Chen, Jin Du, Ruipeng Jia, Hongbin Sun, Zichun Hua, Jun Tang, Feng Wang
We evaluated the clinical utility of 68Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68Ga-PSMA-11 images...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28102507/-44-sc-psma-617-for-radiotheragnostics-in-tandem-with-177-lu-psma-617-preclinical-investigations-in-comparison-with-68-ga-psma-11-and-68-ga-psma-617
#18
Christoph A Umbricht, Martina Benešová, Raffaella M Schmid, Andreas Türler, Roger Schibli, Nicholas P van der Meulen, Cristina Müller
BACKGROUND: The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging ((68)Ga) and radionuclide therapy ((177)Lu) in the clinics. In this study, PSMA-617 was labeled with cyclotron-produced (44)Sc (T 1/2 = 4...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28074210/diagnostic-value-of-additional-68-ga-psma-pet-before-223-ra-dichloride-therapy-in-patients-with-metastatic-prostate-carcinoma
#19
Axel Bräuer, Kambiz Rahbar, Julia Konnert, Martin Bögemann, Lars Stegger
PURPOSE: Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for (223)Ra-dichloride therapy of bone metastases. The purpose of this study was to investigate whether (68)Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for (223)Ra-dichloride therapy. METHODS: In 27 consecutive patients referred for (223)Ra-dichloride therapy additional (68)Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy...
January 11, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28072616/gastrointestinal-stromal-tumor-showing-intense-tracer-uptake-on-psma-pet-ct
#20
Benjamin Noto, Matthias Weckesser, Boris Buerke, Michaela Pixberg, Nemanja Avramovic
A 70-year-old man with suspected prostate cancer was referred for Ga-PSMA-HBED-CC PET/CT (short PSMA PET/CT) for staging of tumor extent. Apart from vivid tracer uptake in the prostate gland and osseous metastasis, PSMA PET/CT revealed a large soft tissue mass with calcifications in the left upper abdomen showing intense tracer uptake. Histologic examination revealed the mass to be a gastrointestinal stromal tumor.
March 2017: Clinical Nuclear Medicine
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"